A multi-center study of 1,593 adults with non-Hodgkin and Hodgkin lymphoma has found that HLA-matched and one-antigen mismatched unrelated donor transplants and cord blood transplants have comparable three-year progression-free survival and overall survival (OS). A multivariate analysis found no significant difference in OS among allogeneic transplants using umbilical cord blood (UCB) and 8/8 unrelated donors (HR 0.87 ; p=0.29), UCB and 7/8 unrelated donors (HR 1.04 [95% CI 0.78-1.40]; p=0.77), and 8/8 and 7/8 unrelated donors (HR 1.19 [95%CI 0.97-1.45; p=0.08).
Bachanova V, et al. BloodChoose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Comparable Outcomes for Unrelated Donor, Cord Blood HCT in Lymphoma
Dec 2013